Federal Register / Vol. 60, No. 34 / Tuesday, February 21, 1995 / Notices 9691

Dated: February 10, 1995.

Louis H. Blair,

Executive Secretary.

[FR Doc. 95–4091 Filed 2–17–95; 8:45 am]

BILLING CODE BOAC–95001–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 94N–0357]

Surveillance System for Antimicrobial

Resistance; Public Hearing; Reopening

of Comment Period

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice; reopening of comment

period.

SUMMARY: The Food and Drug

Administration (FDA) is reopening to

April 1, 1995, the comment period for

the notice of public hearing regarding

approaches to surveillance for the

development of bacterial resistance to

human and animal antimicrobial drugs,

which published in the Federal Register

of October 14, 1994 (59 FR 52168).

Interested persons were given until

February 1, 1995, to submit comments.

FDA is taking this action to provide

interested persons with an opportunity

to comment on submissions received

after the public hearing.

DATES: Submit written comments by

April 1, 1995.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, rm. 1–23, 12420

Parklawn Dr., Rockville, MD 20857.

Two copies of any comments are to be

submitted, except that individuals may

submit one copy. Comments are to be

identified with docket number found in

brackets in the heading of this

document. Received comments may be

seen in the Dockets Management Branch

between 9 a.m. and 4 p.m., Monday

through Friday. Transcripts of the

November 9 and 10, 1994, hearing are

available for review at the Dockets

Management Branch (address above).

FOR FURTHER INFORMATION CONTACT:

Ermona McGoodwin, Center for Drug

Evaluation and Research (HFD–9), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–443–

5455.

SUPPLEMENTARY INFORMATION: In the

Federal Register of October 14, 1994 (59

FR 52168), FDA announced that it

would be holding a public hearing

November 9 and 10, 1994, on

surveillance systems for antimicrobial

resistance. Interested persons were

given until February 1, 1995, to submit

comments. The purpose of the hearing

was to solicit information from, and the

views of, interested persons, including

scientists, professional groups, and

consumers, on the issues and concerns

relating to approaches for regulatory

purposes to surveillance for the

development of bacterial resistance to

antibacterial agents used in humans and

in animals. This hearing was held in

response to a recommendation for

improved surveillance for the

development of antimicrobial resistance

in both animals and humans as

discussed at the May 11 and 12, 1994,

joint meeting of FDA’s Anti-Infective

Drugs Advisory Committee and the

Veterinary Medicine Advisory

Committee (see the Federal Register of

April 15, 1994, (59 FR 18136 at 18137)).

FDA is actively seeking the views of

professional and consumer groups

regarding the implications of an animal

and human bacterial resistance

monitoring system for regulatory

purposes on their constituent

populations. To permit time for all

interested persons to comment on

submissions received after the public

hearing, the administrative record of the

hearing will remain open until April 1,

1995. Persons who wish to provide

additional materials for consideration

should file these materials with the

Dockets Management Branch (address

above) by April 1, 1995.

Dated: February 14, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–4213 Filed 2–17–95; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Institute of Environmental

Health Sciences; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Name of Committee: Environmental Health

Sciences Review Committee

Date: March 27–29, 1995.

Time: 8:30 a.m. to Adjournment.

Place: National Institute of Environmental

Health Sciences, Building 101 Conference

Room, South Campus, Research Triangle

Park, North Carolina.

Contact Person: Dr. Ethel Jackson,

Scientific Review Administrator, P.O. Box

12233, Research Triangle Park, NC 27709,

(919) 541–7826.

Purpose: To review and evaluate grant

applications.

The meeting will be closed in accordance

with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material, and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.113, Biological Response to

Environmental Health Hazards; 93.114,

Applied Toxicological Research and Testing;

93.115, Biometry and Risk Estimation;

93.894, Research and Manpower

Development, National Institutes of Health.)

Dated: February 14, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–4114 Filed 2–17–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Initial

Review Group (IRG) meeting:

Name of IRG: Heart, Lung, and Blood

Program Project Review Committee.

Date: March 23–24, 1995.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy

Chase, Maryland.

Contact Person: Dr. Jeffrey Hurst, 5333

Westbard Avenue, Room 555, Bethesda,

Maryland 20892, (301) 594–7418.

Purpose/Agenda: To review and evaluate

grant applications.

The meeting will be closed in accordance

with the provisions set forth in sec.

552(b)(c)(4) and 552(c)(6), Title 5, U.S.C.

Applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health.)

Dated: February 14, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95–4112 Filed 2–17–95; 8:45 am]

BILLING CODE 4140–01–M